Apply Now
Innovation in life sciences is global. Scientific breakthroughs defy borders and their impact depends on global scaling. We bridge exceptional local science with global opportunities, leveraging Bayer's worldwide footprint, deep scientific expertise, and access to key innovation hubs to accelerate start-up growth. We empower emerging companies to navigate new markets and bring their brilliant ideas to life that help reach patients worldwide.
Bayer Co.Lab Connect launches region-specific programs designed to identify and support outstanding local science while removing barriers to international expansion. Selected companies gain exposure to global Bayer Co.Lab sites, deep scientific expertise, and trusted regional partners—allowing them to explore new markets while remaining rooted in their local innovation ecosystems.
Introducing Our 2025 Co.Lab Connect Winner:
NXI Therapeutics & Rege Nephro Co. Ltd
In 2025, Bayer named Rege Nephro (Japan) and NXI Therapeutics (Switzerland) as the inaugural companies selected for the Bayer Co.Lab Connect program, an initiative designed to help high‑potential startups expand globally by bridging them into the life science innovation ecosystem. Identified through targeted outreach, both companies stood out for their strong scientific foundations and close alignment with Bayer’s strategic priorities.
Learn more about our Co.Lab Connect Basel program
Read moreLearn more about our Co.Lab Connect Seoul program
Read more